Last update 29 Nov 2024
Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)
Last update 29 Nov 2024
Overview
Basic Info
Drug Type CAR-T |
Synonyms IM96 CAR-T细胞, IM-96 |
Target |
Mechanism GC-C antagonists(Heat-stable enterotoxin receptor antagonists), Gene transference, T lymphocyte replacements |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
评估IM96 CAR-T细胞注射液治疗晚期结直肠癌的安全性和有效性的I期临床研究
[Translation] A phase I clinical study to evaluate the safety and efficacy of IM96 CAR-T cell injection in the treatment of advanced colorectal cancer
100 Clinical Results associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)
Login to view more data
100 Translational Medicine associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)
Login to view more data
100 Patents (Medical) associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)
Login to view more data
100 Deals associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 1 | CN | 21 Nov 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 10 Mar 2022 | |
| Pancreatic Cancer | Phase 1 | CN | 10 Mar 2022 | |
| Stomach Cancer | Preclinical | CN | 01 Nov 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05287165 (ASGCT2024) Manual  | Phase 1 | 20 | IM96 | ckhgynjtnd(jpdvirhvcw) = Only 1/20 pt (5.0%) showed neurotoxicity and ≥grade 3 cytokine release syndromes (CRS). Grade 1-2 CRS occurred in 16/20 pts (80.0%) with dramatic increase of interleukin-6. Grade 1-3 rash was observed in 14/20 pts (70.0%). Grade 3 diarrhea occurred in 11/20 pts (55.0%), and grade 1-3 oral mucositis appeared in 7/20 pts (35.0%), only in DL2, DL3 and DL4 groups. khafsvecuh (lfdcosoeva ) View more | Positive | 23 Apr 2024 | |
NCT05287165 (ESMO2023) Manual | Phase 1 | 9 | cijdehmnij(lzunfcfxqm) = wcfrnbsvdt tazetwggce (uwguwieyfh ) View more | Positive | 23 Oct 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free